E-viri
Recenzirano
Odprti dostop
-
Smith, Matthew R; Hussain, Maha; Saad, Fred; Fizazi, Karim; Sternberg, Cora N; Crawford, E. David; Kopyltsov, Evgeny; Park, Chandler H; Alekseev, Boris; Montesa-Pino, Álvaro; Ye, Dingwei; Parnis, Francis; Cruz, Felipe; Tammela, Teuvo L.J; Suzuki, Hiroyoshi; Utriainen, Tapio; Fu, Cheng; Uemura, Motohide; Méndez-Vidal, María J; Maughan, Benjamin L; Joensuu, Heikki; Thiele, Silke; Li, Rui; Kuss, Iris; Tombal, Bertrand
The New England journal of medicine, 03/2022, Letnik: 386, Številka: 12Journal Article
Standard therapy for metastatic, hormone-sensitive prostate cancer is androgen-deprivation therapy, usually with docetaxel. A large, multinational, phase 3 trial assessed the addition of the androgen-receptor blocker darolutamide to standard therapy. At 4 years, survival was higher with darolutamide than with placebo (62.7% vs. 50.4%), with no major differences in the frequency of adverse events.
